Oak Family Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.4M Buy
320,656
+71,911
+29% +$3.09M 3.93% 3
2026
Q1
$9.14M Sell
248,745
-25,483
-9% -$1.21M 2.57% 8
2025
Q4
$14M Buy
274,228
+121,143
+79% +$6.19M 3.83% 4
2025
Q3
$8.49M Buy
153,085
+11,705
+8% +$685K 2.12% 10
2025
Q2
$9.76M Buy
141,380
+55,027
+64% +$3.74M 3.08% 7
2025
Q1
$6M Buy
+86,353
New +$7.13M 2.02% 14

Other funds holding NVO

Oak Family Advisors's NVO Position: Q2 2026 in Review

Oak Family Advisors increased its Novo Nordisk (NVO) stake by 29% in Q2 2026, buying an estimated $3.09M and bringing the position to 320,656 shares worth $15.4M. The position accounts for 3.93% of the portfolio, ranked #3.

Oak Family Advisors first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Oak Family Advisors held 320,656 shares of Novo Nordisk worth $15.4M as of Q2 2026.
  • Oak Family Advisors bought 71,911 Novo Nordisk shares in Q2 2026, an estimated $3.09M.
  • Novo Nordisk made up 3.93% of Oak Family Advisors's portfolio in Q2 2026, its #3 holding.
  • Oak Family Advisors first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Oak Family Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.